OWC Pharmaceutical Research Corp (OWCP)

[EasternTimeZone]

OWCP Patent links (7 patent families, 31 patents, and counting) All are active, zero patents rejected. These patents are being amended to perfection.  People that actually know about the patent process know that it's a process.


Here are their latest revisions in February 2018.

https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf

https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf

https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf


United States Patent and Trademark Office (USPTO) (search from the Patent Application Information Retrieval (PAIR) (patent application # 15536738 and 15629230, and 15708187))

https://www.uspto.gov/patents-application-process/search-patents


World Intellectual Property Organization (simple search One World Cannabis)

https://patentscope.wipo.int/search/en/result.jsf


European Patent Register

https://register.epo.org/smartSearch?searchMode=smart&query=one+world+cannabis


IP Australia

http://pericles.ipaustralia.gov.au/ols/auspat/quickSearch.do?queryString=one+world+cannabis&resultsPerPage=


Canadian Intellectual Property Office

http://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=one+world+cannabis&start=1&num=50&type=basic_search&newSearch=0


Israel Patent Office (click English in top left, then advance search for applicant One World Cannabis)

http://www.ilpatsearch.justice.gov.il/UI/RequestsList.aspx



Dr. Yehuda Baruch stated, “We greatly look forward to introducing this breakthrough tablet to the marketplace”

Dr. Rozenblat stated, "as a scientist I am extremely excited to be part of OWC's study that appears to be a highly possible breakthrough".


And then, on February 18, 2018, OWC Pharmaceutical Research Corp., OTCQB: OWCP, appointed Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO).

Dr Zeevi is an expert in this kind of R&D and getting patents granted and it's very likely that she read every patent application as well as reviewed all of the work OWCP had done before joining the OWCP team. There's no way she would have joined OWCP if it was not legit.

Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.

Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem

Dr. Yehuda Baruch who, will now assume the role of Chief Medical and Regulatory Officer of the OWC Pharmaceutical Research Corp. commented:

"I am very pleased that we have reached a stage in our development where we were able to recruit a scientist of the caliber and background of Dr. Yacoby Zeevi. Her past scientific experience and achievements will greatly benefit our endeavors."

Dr. Yacoby Zeevi commented, "I am very proud to join OWCP and cooperate with their excellent management team in order to advance the Company to the next level. The Company has achieved a great deal in its clinical development to date and I am sure I can help in accelerating its growth."

Mr. Mordechai Bignitz, Chief Executive Officer, commented on the appointment, "I am proud and honored to have Dr. Zeevi agree to join OWCP and assume the role of CSO. She brings with her immense pharmaceutical discovery and development knowledge, a unique set of skills and an exceptional track record, which contributed significantly to the success of her previous company. Her addition will complement our management team extremely well."


Read it all, do your own DD.



$OWCP Long and Strong.... $$$$$ GOING TO BE HUGE! $$$$$